Soluble E-selectin in multiple sclerosis: Raised concentrations in patients with primary progressive disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 60, Issue 1, 1996, Pages 20-26

  Giovannoni, Gavin ^a   Thorpe, J W ^b   Kidd, D ^b   Kendall, B E ^b   Moseley, I F ^b   Thompson, A J ^b   Keir, G ^a   Miller, D H ^b   Feldmann, M ^c   Thompson, E J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Multiple Sclerosis   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

E selectin; Gadolinium enhancement; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GADOLINIUM PENTETATE; MARKER; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; BRAIN; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; SPINAL CORD;

EID: 0030070703     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.60.1.20     Document Type: Article

References (48)

1. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113:1477-89.
2. Hawkins CP, Munro PMG, Mackenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990;113:365-78.
3. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-9.
4. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-36.
5. Hauser SL, Bhan AK, Gilles F, et al. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986;19:578-87.
6. Antel JP, Owens T. The attraction of adhesion molecules. Ann Neurol 1993;34:123-4.
7. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 1993;11:767-804.
8. Lobb RR, Chirosso G, Leone, DR, et al. Expression and functional characterisation of a soluble form endothelial leukocyte adhesion molecule-1. J Immunol 1991;147: 124-9.
9. Gearing JH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:5067.
10. Hartnung H-P, Reiners K, Mchels M, et al. Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies. Neurology 1994;44:1153-8.
11. Oka N, Akiguchi I, Kawasaki T, et al. Elevated serum levels of endothelial leukocyte adhesion molecules in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Ann Neurol 1994;35:621-24.
12. Brinkhous KM, Sulzer DL, Reddick RL et al. Elevated plasma von Willebrand factor levels as an index of acute endothelial injury: use of a hypotonic injury model in rats. Federation Proceedings 1980;39:630.
13. Nusinow SR, Federici AB, Zimmerman TS et al. Increased von Willebrand factor antigen in the plasma of vasculitis. Arthritis Rheum 1984;27:1405-10.
14. Porta M, Townsend C, Clover GM et al. Evidence of functional endothelial cell damage in early diabetic retinopathy. Diabetologica 1981;20:597-601.
15. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
16. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
18. Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and course of multiple sclerosis. Acta Neurol Scand 1982;66:355-62.
19. Leeuwenberg JFM, Smeets EF, Neefjes JJ, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-9.
20. Sharief MK, Hentges R. Association between tumour necrosis factor-α and disease progression in multiple sclerosis. N Engl J Med 1991;325:467-72.
21. Riches P, Gooding R, Millar BC, Rowbottom AW. Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-α concentrations. J Immunol Methods 1992;153:125-31.
22. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-8.
23. Dore-Duffy P, Newman W, Balabanov R, et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 1995;37:55-62.
24. Van Lambalgen R, Sanders EACM, D'Amaro J. Distribution, age of onset and HLA profiles in two types of multiple sclerosis. J Neurol Sci 1986;76:13-21.
25. Madigand M, Oger JJ-f, Fauchet R, et al. HLA Profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci 1982;53: 519-29.
26. Olerup O, Hillert J, Olsson T, et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: Two immunogenetically distinct disease entities. Proc Natl Acad Sci USA 1989;86:7113-7.
27. Hillert J, Grönning M, Nyland H, et al. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:887-90.
28. Larsen JP, Kvaale G, Riise T, et al. Multiple sclerosis - more than one disease? Acta Neurol Scand 1985;72: 145-50.
29. Revesz T, Kidd D, Thompson AJ, et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994;117:759-65.
30. Rieckmann P, Martin S, Weichselbraun I, et al. Serial analysis of circulating adhesion molecules and the TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator of relapse. Neurology 1994; 44:2367-72.
31. Mobner R, Fassbender K, Schwartz A, Hennerici M. Vascular cell adhesion molecule - a novel approach to detect endothelial cell activation in MS in vivo. J Neurol 1994;241(suppl 1):S89-90.
32. Ishikawa T, Imura A, Tanaka K, et al. E-selectin and vascular cell adhesion molecule-1 mediate adult T-cell leukemia cell adhesion to endothelial cells. Blood 1993; 82:1590-8.
33. Gamble JR, Khew-Goodall Y, Vadas MA. Transforming growth factor-β inhibits E-selectin expression on human endothelial cells. J Immunol 1993;150:4494-503.
34. Beck J, Rondot P, Jullien P, et al. TGF-β-like activity produced during regression of exacerbations in multiple sclerosis. Acta Neurol Scand 1991;84:452-5.
35. Link J, Fredrikson S, Södersteröm M, et al. Organ-specific autoantigens induce transforming growth factor-β mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 1994;44:728-34.
36. Raine CS, Canella B. Multiple sclerosis: adhesion molecule and cytokine profiles in lesions of different ages. Neurology 1994;44:556S.
37. Racke MK, Cannella B, Albert P, et al. Evidence of endogenous regulatory function of transforming growth factor-β1 in experimental allergic encephalomyelitis. Int Immunol 1992;4:615-20.
38. Racke MK, Sriram S, Carlino J, et al. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β2. J Neuroimmunol 1993;46:175-84.
39. Kuruvilla AP, Shah R, Hochwald GM, et al. Protective effect of transforming growth factor β1 on experimental diseases in mice. Proc Natl Acad Sci USA 1991;88: 2918-21.
40. Kim DS, Lee KY. Serum-soluble E-selectin levels in Kawasaki-disease. Scand J Rheum 1994;23:283-6.
41. Santosneto L, Munizjunqueira M, Tosta CE. Severe cases of Plasmodium falciparum malaria show increased plasma levels of both E-selectin and tumour necrosis factor alpha. Clin Res 1994;42:A283.
42. Dowling PC, Cook SD. Disease markers in acute multiple sclerosis. Arch Neurol 1976;33:668-70.
43. Schuller E, Allinquant B. Determination of C-reactive protein by electroimmunodiffusion in blood and CSF of neurological patients. Eur Neurol 1973;9:216-33.
44. Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous tissue. Brain 1991;114:1013-23.
45. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
46. Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 1992;13:507-12.
47. Zaman AG, Edelstein C, Stanford MR, et al. Soluble intercellular adhesion molecule-1 (sICAM-1) as a marker of disease relapse in idiopathic uveoretinitis. Clin Exp Immunol 1994;95:60-5.
48. Paleolog EM, Carew MA, Pearson JD. Effects of tumour necrosis factor and interleukin-1 on von Willebrand factor secretion from human vascular endothelial cells. Int J Radiat Biol 1991;60:279-85.